Related Experiment Video
Updated: Jan 28, 2026

Performing Vaginal Lavage, Crystal Violet Staining, and Vaginal Cytological Evaluation for Mouse Estrous Cycle Staging Identification
Published on: September 15, 2012
Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation
Kristina Gemzell-Danielsson1, Regine Sitruk-Ware2, Mitchell D Creinin3
1Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden.
The 1-year segesterone acetate/ethinyl estradiol contraceptive vaginal system (CVS) demonstrates an acceptable safety profile for women seeking long-term birth control. Further research is recommended for obese women due to potential venous thromboembolism risks.
Area of Science:
- Reproductive Health
- Contraception
- Clinical Safety Studies
Background:
- Combination hormonal contraceptives are widely used for birth control.
- New delivery systems for hormonal contraception are being developed to improve user experience and efficacy.
- The segesterone acetate/ethinyl estradiol contraceptive vaginal system (CVS) offers a long-term, user-controlled option.
Purpose of the Study:
- To evaluate the safety outcomes of a 12-month contraceptive vaginal system (CVS) releasing segesterone acetate (SA) and ethinyl estradiol (EE).
- To assess adverse events, expulsions, and specific safety parameters associated with the CVS.
- To compare the safety profile of the CVS with existing combination hormonal contraceptives.
Main Methods:
- Integrated clinical safety data from nine studies involving 3052 women using the CVS.
- Assessed safety through daily adverse event diaries and focused safety studies (endometrial biopsies, vaginal microbiology, liver proteins).
- Analyzed data from studies using the final manufactured CVS, including pharmacokinetic and Phase 3 trials.
Main Results:
- The most common adverse events reported were headache (26%), nausea (18%), vaginal discharge/mycotic infection (10%), and abdominal pain (10%).
- Few women (<1.5%) discontinued use due to adverse events.
- Four women (0.2%) experienced venous thromboembolism (VTE), with three having pre-existing risk factors. Expulsion rates were 19.5% partial and 7% complete per cycle.
Conclusions:
- The 1-year SA/EE CVS exhibits an acceptable safety profile, comparable to other combination hormonal contraceptives.
- The same precautions for prescribing combination hormonal contraceptives should be applied to this new CVS.
- Additional studies are warranted to investigate safety in obese women at higher risk for VTE.
Related Concept Videos
Survey Safety
Acetals and Thioacetals as Protecting Groups for Aldehydes and Ketones
In the presence of multiple functional groups, when selective reduction of one group over the other is desired, groups like aldehydes and ketones that form acetals...
Household Wiring And Electrical Safety
Self-Evaluation: Self-Enhancement and Self-Verification
Nursing Evaluation
Self-Evaluation Maintenance Model

